These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S; Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687 [TBL] [Abstract][Full Text] [Related]
7. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M; Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405 [TBL] [Abstract][Full Text] [Related]
8. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC; Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560 [TBL] [Abstract][Full Text] [Related]
9. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748 [TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma. Gueneau P; Chretien ML; Cransac-Miet A; Aho LS; Lafon I; Favennec C; Guy J; Caillot D; Boulin M Eur J Haematol; 2018 May; 100(5):518-525. PubMed ID: 29393533 [TBL] [Abstract][Full Text] [Related]
11. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Siegel DS; Schiller GJ; Samaras C; Sebag M; Berdeja J; Ganguly S; Matous J; Song K; Seet CS; Talamo G; Acosta-Rivera M; Bar M; Quick D; Anz B; Fonseca G; Reece D; Pierceall WE; Chung W; Zafar F; Agarwal A; Bahlis NJ Leukemia; 2020 Dec; 34(12):3286-3297. PubMed ID: 32376855 [TBL] [Abstract][Full Text] [Related]
12. Acute lung toxicity related to pomalidomide. Geyer HL; Viggiano RW; Lacy MQ; Witzig TE; Leslie KO; Mikhael JR; Stewart K Chest; 2011 Aug; 140(2):529-533. PubMed ID: 21813533 [TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients. Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928 [TBL] [Abstract][Full Text] [Related]
15. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone. Dimopoulos MA; Weisel KC; Song KW; Delforge M; Karlin L; Goldschmidt H; Moreau P; Banos A; Oriol A; Garderet L; Cavo M; Ivanova V; Alegre A; Martinez-Lopez J; Chen C; Spencer A; Knop S; Bahlis NJ; Renner C; Yu X; Hong K; Sternas L; Jacques C; Zaki MH; San Miguel JF Haematologica; 2015 Oct; 100(10):1327-33. PubMed ID: 26250580 [TBL] [Abstract][Full Text] [Related]
16. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Richardson PG; Perrot A; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Malinge L; Dubin F; van de Velde H; Anderson KC Lancet Oncol; 2022 Mar; 23(3):416-427. PubMed ID: 35151415 [TBL] [Abstract][Full Text] [Related]
17. Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma. Pierceall WE; Amatangelo MD; Bahlis NJ; Siegel DS; Rahman A; Van Oekelen O; Neri P; Young M; Chung W; Serbina N; Parekh S; Agarwal A; Thakurta A Clin Cancer Res; 2020 Nov; 26(22):5895-5902. PubMed ID: 32928795 [TBL] [Abstract][Full Text] [Related]
18. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series. Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321 [No Abstract] [Full Text] [Related]
19. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment. Matsue K; Sunami K; Matsumoto M; Kuroda J; Sugiura I; Iwasaki H; Chung W; Kuwayama S; Nishio M; Lee K; Iida S Int J Hematol; 2022 Jul; 116(1):122-130. PubMed ID: 35429329 [TBL] [Abstract][Full Text] [Related]